Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy 1.7mg is the fourth dose in the semaglutide titration schedule, taken once weekly by subcutaneous injection. It sits between the 1mg step and the 2.4mg maintenance dose, and most people reach it at around week thirteen of treatment. As a prescription-only medicine, semaglutide requires clinical assessment before it can be prescribed — a prescriber decides when, and whether, you move to this level. For a clear picture of where 1.7mg fits across the full schedule, the Wegovy dose guide covers every step in sequence.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The titration ladder for Wegovy exists to protect tolerability, not to delay results. Semaglutide slows gastric emptying and suppresses appetite through GLP-1 receptor activation, and the body needs time to adjust at each level before the dose climbs again. The 0.25mg and 0.5mg steps are primarily about settling the system. By 1mg, many people start to notice meaningful appetite reduction. The 1.7mg step pushes that effect further while still giving the body a four-week runway before the full 2.4mg maintenance dose.
Skipping steps is not how this works clinically. Each increase is reviewed by a prescriber, at nume, a GPhC-registered Independent Prescriber reads your consultation before every repeat, not a piece of software. If tolerability has been poor, staying at a lower dose for longer is a legitimate clinical decision. The 1.7mg pen is there as a genuine therapeutic rung, not just a waypoint.
The 1.7mg dose overview goes into more detail on what the prescribing guidance says about this specific level.
Most side effects with semaglutide are gastrointestinal, and they tend to be more pronounced after a dose increase than during a settled period at the same dose. At 1.7mg, nausea is the most commonly reported symptom, followed by constipation, diarrhoea, vomiting and indigestion. For most people these ease within a week or two as the body adjusts. Fatigue and mild headache are also reported, though less frequently.
There is an honest thing worth saying here: reaching 1.7mg and finding the side effects harder than expected is genuinely discouraging, especially if you have already pushed through discomfort at lower steps. That experience is common. Eating smaller meals, staying well hydrated and avoiding high-fat foods during the adjustment period are the practical measures the NHS highlights for managing GI effects on semaglutide, the NHS semaglutide page covers these in plain language.
Serious symptoms (severe abdominal pain that radiates to the back, signs of an allergic reaction, or symptoms of gallbladder problems) need prompt medical attention. The Wegovy information page covers the full side-effect profile and when to seek urgent help.
The standard schedule is four weeks at each dose step, so 1.7mg typically runs from roughly week thirteen to week sixteen before the prescriber considers moving to 2.4mg. That said, some people stay at 1.7mg longer, either because tolerability needs more time, or because the prescriber judges that clinical progress at this level warrants it. Maintenance at 1.7mg rather than 2.4mg is an option in some cases, though 2.4mg is the standard maintenance dose under the UK licence.
The transition from 1mg to 1.7mg is a useful read if you are currently on the third step and wondering what changes. And if you want to understand how the injection itself is used at this dose, the 1.7mg Wegovy pen guide has the practical detail, though always defer to the Patient Information Leaflet supplied with your medicine and your prescriber's instructions for anything specific to your prescription.
For context on how weight loss typically progresses across the full schedule, the STEP 1 trial (published in the New England Journal of Medicine) reported an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, with most participants having diabetes excluded. The 1.7mg step contributes to that trajectory, it is part of the journey, not the destination. NICE's appraisal of semaglutide for weight management, TA875, provides the UK clinical framework for how the medicine is assessed and recommended.
Private treatment through a regulated online pharmacy means there is no NHS waiting list and no referral needed, but clinical rigour is the same. Every dose step, including the move to 1.7mg, is reviewed before the next pen is dispatched. The click guide for the 1.7mg pen and the 1.7mg click chart can help if you want to understand the injection mechanics for this specific dose ahead of your next clinical review.
Private Wegovy prescriptions vary in cost by dose, and the private Wegovy cost and access page explains what a legitimate prescription typically includes. One transparent price at nume covers consultation, prescription, next-working-day tracked delivery and seven-day aftercare, no subscription, no auto-renewal. Treatment pricing is shown on the treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.